How has been the historical performance of Natco Pharma?

Answer:The historical performance of Natco Pharma shows significant growth in various financial metrics over the years.

Breakdown:
Natco Pharma's net sales have steadily increased from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025. The company has managed to improve its operating profit (PBDIT) from 690.00 Cr in March 2020 to 2,550.50 Cr in March 2025, indicating enhanced operational efficiency. Profit before tax also saw a significant rise, climbing from 568.70 Cr in March 2020 to 2,291.40 Cr in March 2025. Consequently, profit after tax surged from 458.10 Cr in March 2020 to 1,883.40 Cr in March 2025, showcasing strong profitability. The earnings per share (EPS) increased dramatically from 25.32 in March 2020 to 105.33 in March 2025, reflecting improved shareholder value. On the balance sheet, total assets grew from 4,587.80 Cr in March 2020 to 8,580.70 Cr in March 2025, while total liabilities increased from 4,587.80 Cr to 8,580.70 Cr over the same period. The cash flow from operating activities also improved, rising from 417.00 Cr in March 2020 to 1,696.00 Cr in March 2025, indicating a strong cash generation capability. Overall, Natco Pharma has demonstrated a strong upward trend in its financial performance across multiple dimensions.